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Abstract
Background: To date, there are no highly sensitive and specific minimally invasive biomarkers for detection of breast cancer
at an early stage. The occurrence of circulating microRNAs (miRNAs) in blood components (including serum and plasma) has
been repeatedly observed in cancer patients as well as healthy controls. Because of the significance of miRNA in
carcinogenesis, circulating miRNAs in blood may be unique biomarkers for early and minimally invasive diagnosis of human
cancers. The objective of this pilot study was to discover a panel of circulating miRNAs as potential novel breast cancer
biomarkers.
Methodology/Principal Findings: Using microarray-based expression profiling followed by Real-Time quantitative
Polymerase Cycle Reaction (RT-qPCR) validation, we compared the levels of circulating miRNAs in plasma samples from
20 women with early stage breast cancer (10 Caucasian American (CA) and 10 African American (AA)) and 20 matched
healthy controls (10 CAs and 10 AAs). Using the significance level of p,0.05 constrained by at least two-fold expression
change as selection criteria, we found that 31 miRNAs were differentially expressed in CA study subjects (17 up and 14
down) and 18 miRNAs were differentially expressed in AA study subjects (9 up and 9 down). Interestingly, only 2
differentially expressed miRNAs overlapped between CA and AA study subjects. Using receiver operational curve (ROC)
analysis, we show that not only up-regulated but also down-regulated miRNAs can discriminate patients with breast cancer
from healthy controls with reasonable sensitivity and specificity. To further explore the potential roles of these circulating
miRNAs in breast carcinogenesis, we applied pathway-based bioinformatics exploratory analysis and predicted a number of
significantly enriched pathways which are predicted to be regulated by these circulating miRNAs, most of which are
involved in critical cell functions, cancer development and progression.
Conclusions: Our observations from this pilot study suggest that the altered levels of circulating miRNAs might have great
potential to serve as novel, noninvasive biomarkers for early detection of breast cancer.
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Introduction
Discovery of sensitive and specific minimally invasive biomark-
ers that can be exploited to detect early neoplastic changes, thus
facilitating the detection of breast cancer at an early stage, is one of
the most important challenges in the management of breast
cancer. The ideal biomarker should be easily accessible such that it
can be sampled relatively noninvasively, sensitive enough to detect
early presence of tumors in almost all patients, and absent or
minimally present in healthy, tumor free individuals. Unfortu-
nately, none of the existing diagnostic tools and biomarkers for
breast cancer meets the above criteria [1–3]. For example,
mammography, currently the gold standard diagnostic tool, needs
to use ionizing radiation and has a false positive rate of 8% to 10%
[1]. A number of circulating tumor markers, such as carcinoem-
bryonic antigen and carbohydrate antigen 15–3, have shown
promise in the management of breast cancer, but the sensitivity of
these markers is low, and so they are not useful for the early
detection of breast cancer [4–6]. Clearly, the development of
minimally or noninvasive, highly sensitive and specific breast
cancer biomarkers which can complement and improve on
current strategies for breast cancer detection is urgently needed.
In the last decades, the relationship between microRNA
(miRNA) and human cancer has been extensively investigated.
Research has shown that miRNAs are deregulated in a widespread
manner in almost every type of human cancer, and the signature
of miRNA expression in tumors can be potentially used as
biomarkers for tumor characterization and cancer prognosis [7–
19]. Circulating RNAs have been identified in the serum/plasma
of cancer patients for more than a decade. Recently, several
studies have reported the occurrence of circulating miRNAs in
serum and plasma samples from both cancer patients and healthy
controls [20–28]. For example, in colorectal cancer, Huang et al
[27] found plasma miRNAs were highly sensitive for detecting
colorectal cancer and advanced adenomas, and that miR-29a and
miR-92a were associated with advanced neoplasia. To further
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the levels of miR-29a and miR-92a expression in plasma samples
harvested from pre-operative and post-operative bloods and found
a significant reduction in both miRNAs compared to the pre-
operative samples of the same patients. In breast cancer,
Heneghan et al [26] surveyed a panel of 7 candidate miRNAs in
whole blood RNAs from 148 breast cancer patients and 44 age-
matched and disease free controls. They found the expression of
miR-195 was significantly elevated in breast cancer patients.
Additionally, they observed a significant reduction in miR-195 in
post-operative whole blood compared to the pre-operative samples
of the same patients.
Using microarray-based expression profiling, the goal of this
pilot study was to identify a panel of circulating miRNAs which
are differentially expressed in plasma samples from breast cancer
patients and matched healthy controls, and to examine if there
were differences in circulating miRNA expression between
Caucasians Americans (CAs) and African Americans (AAs). We
also aimed to apply bioinformatics tools to explore the potential
biological function of identified candidate miRNAs.
Materials and Methods
Study population
The study has been approved by Institutional Research Board
(IRB) of Roswell Park Cancer Institute. Anonymized biospecimens
and questionnaire data used in this study were made available
through the Roswell Park Cancer Institute’s (RPCI) Data Bank
and BioRepository (DBBR) [29]. Patients are enrolled through
site-specific clinics prior to surgery and/or chemotherapy, and
controls are individuals who are free from cancer and are visitors
or family members of patients. Relationships between patients and
controls are carefully annotated, so that we avoid overmatching
patients to their own family or friends. Written consent is obtained
from every individual before he/she enrolls in the DBBR. The
consent will allow DBBR to provide anonymized biospecimens
and questionnaire data for research (such as this study) without
further consent. Patients and controls are consented to provide a
non-fasting blood sample and to complete a questionnaire. Blood
samples are drawn in phlebotomy and transferred to the DBBR
laboratory. Following DBBR standard operating procedure (SOP),
samples are processed and blood components stored within one
hour of collection to minimize degradation. Ten milliliters of
whole blood was obtained from each study subject. Plasma was
extracted by centrifuging whole blood at 3,000 rpm for 10 minutes
at room temperature. All extracted plasma samples are stored in
phased liquid nitrogen. To minimize the effect of freeze-thaw on
circulating miRNAs, we only used plasma samples which had not
been previously thawed. In this study, a total of 20 women with
breast cancer and 20 cancer-free women were included in the
microarray profiling analysis. Same AA study participants (10 AA
cases and 10 AA controls) were included in the RT-qPCR
validation analysis. The CA study participants (15 CA cases and
15 CA controls) included in RT-qPCR validation analysis were
also obtained from DBBR, but they were different from the ones
used in microRNA profiling.
RNA isolation
Total RNA, including miRNA from plasma, was isolated using
the miRNeasy kit (Qiagen) with minor modifications. In brief,
700 ml of QIAzol reagent was added to 200 ml of plasma sample.
The sample was mixed in a tube, followed by the addition of 3 ml
of miSPIKE, spiked-in miRNA, at a concentration of 0.1 mM
(IDT) and 140 ml of chloroform. After mixing vigorously for 15 s,
the sample was then centrifuged at 12,000 g for 15 minutes. The
upper aqueous phase was carefully transferred to a new collection
tube, and 1.5 volume of ethanol was added. The sample was then
applied directly to a silica membrane-containing column and the
RNA was bound and cleaned using buffers provided by the
manufacturer to remove impurities. The immobilized RNA was
then collected from the membrane with a low salt elution buffer.
The quality and quantity of the RNA was evaluated by 260/280
ratio using NanoDrop spectrophotometry (NanoDrop ND-1000
Technologies Inc.) and Agilent 2100 Bioanalyzer (Agilent
Technologies). The efficiency of small RNA isolation was
monitored by the amount of spiked-in miRNA recovered by
using PCR with sequence specific primers (IDT).
MicroRNA Quantification of miRNA Expression
Two hundred ng of total RNA from each sample were labeled
and hybridized on Human v2 MicroRNA Expression BeadChips
(Cat. no. MI-102–1024; Illumina), according to the manufacturers
recommendations (Illumina MicroRNA Expression Profiling
Assay Guide). The raw intensity of Illumina Plasma V2
MicroRNA expression array was scanned and extracted using
BeadScan, with the data corrected by background subtraction in
Table 1. Differentially expressed microRNAs (P,0.05) with at
least two-fold change obtained from case-versus-control
comparisons in specimens of all 40 participants.
All participants (Case vs. Control)
MicroRNA name Log2 FC P value AUC
hsa-miR-595 2.395719 0.002393 0.75
hsa-miR-589 2.155282 0.006985 0.6
hsa-miR-504 1.915404 0.025783 0.68
hsa-miR-518b 1.600464 0.035285 0.67
hsa-miR-483-5p 1.385806 0.037231 0.56
hsa-miR-425* 1.197242 0.027131 0.68
hsa-miR-493 1.144993 0.032888 0.7
hsa-miR-187 1.144919 0.038317 0.62
hsa-miR-431* 1.107432 0.025801 0.62
hsa-miR-1231 1.028423 0.023928 0.68
solexa-9655-85 1.003729 0.026531 0.7
hsa-miR-668 21.00174 0.038456 0.68
hsa-miR-377 21.08111 0.048523 0.66
hsa-miR-410 21.17687 0.039992 0.64
hsa-miR-922 21.24073 0.029972 0.64
hsa-miR-155 21.26546 0.014117 0.72
HS_169 21.29076 0.023019 0.69
hsa-miR-340* 21.50691 0.019858 0.66
HS_200 21.53419 0.049367 0.7
hsa-miR-432 21.60309 0.047606 0.65
hsa-miR-574-3p 21.66389 0.037904 0.67
hsa-miR-148a 21.68157 0.034794 0.66
hsa-miR-181a 22.00397 0.004354 0.72
hsa-miR-1275 22.00526 0.008116 0.72
hsa-miR-1304 22.51079 0.002657 0.7
hsa-miR-151-5p 22.81719 0.000542 0.76
doi:10.1371/journal.pone.0013735.t001
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Bioconductor Package was used to normalize the log2 transformed
intensity data with the Quantile normalization algorithm. The
expression profiles have been deposited in NCBI’s Gene
Expression Omnibus (GEO) with accession number GSE22981.
microRNA MicroArray Data Analysis
All data analysis was performed under R programming
environment (www.r-project.org). Differential Expression Testing For
the 40 subjects, we compared cases and controls stratified by race/
ethnicity. We used the Limma program in the R-based
Bioconductor package to calculate the level of differential
expression for each comparison. Briefly, for each comparison, a
linear model was fit to the data (with cell means corresponding to
the different conditions and a random effect for array) [30]. For
each comparison, we obtained the list of differentially expressed
microRNA constrained by P-value less than 0.05 and then
checked for candidates with at least two-fold expression change.
Clustering Following single miRNA-based significance testing, we
used the expression value of miRNAs (P value ,0.05 and at least
two-fold expression) to cluster the patients for each comparison.
Our purpose was to check whether the identified miRNAs for each
comparison, as a whole, were able to serve as potential miRNA
signature to classify patients into their corresponding case/control
status. Hierarchical clustering based on the average linkage of
Pearson Correlation was employed [31]. The expression value of
the same miRNA lists was also used as the input for Principal
Component Analysis (PCA). Briefly, the 1st principal component
(i.e., the direction along which the miRNAs show largest variation)
and the 2nd principle component (i.e., the direction uncorrelated
to the 1st component along which the miRNAs show the largest
deviation) were shown to capture the clustering structures. The
PCA implementation here is based on the single value decompo-
sition (SVD) package. ROC curve analysis The expression profile of
each identified miRNA was used as the input for Receive
Characteristics Curve (ROC) analysis with the ROCR package
[32]. ROC curve is displayed as the True Positive Rate (TPR)
versus the False Positive Rate (FPR). The area under the ROC
Figure 1. Characteristics of differentially expressed microRNAs (P,0.05 & FC .2) obtained from the case-versus-control
comparison using all 40 participants. A–B) Hierarchical clustering and principal component clustering of differentially expressed microRNAs C)
The overlap of differentially expressed microRNAs obtained from all 40 participants with those from AA group only (20 participants) and CA group
only (20 participants), respectively.
doi:10.1371/journal.pone.0013735.g001
Table 2. Summary of the number of differentially expressed miRNAs obtained from comparisons (case vs. control) in specimens
from AA and CA participants, respectively.
Case vs. Control
AA group CA group Overlap
Number of Patients 10 vs. 10 10 vs. 10















‘: Up-regulated in the case vs control comparison.
*: Down-regulated in the case vs control comparison.
doi:10.1371/journal.pone.0013735.t002
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Pathway Enrichment Analysis Using TargetScan (http://www.targetscan.
org), we obtained the list of genes predicted to be targeted by the
miRNAs identified from each comparison. The predicted miRNA
target genes were analyzed for enriched KEGG pathways by using the
NCBI DAVID server (http://david.abcc.ncifcrf.gov) with default
setting, in which the null hypothesis is that no difference exists between
the number of genes falling into a given pathway in the target gene list
and the genome as a whole [33].
Real-time quantitative PCR analysis
The expression levels of miRNA were confirmed with a
Taqman-based real-time quantitative PCR (RT-qPCR) using
individual miRNA-specific primers and probes as described by
the manufacturer (Applied Biosystems). The first-strand miRNA-
cDNA PCR template was generated from 50 ng of total RNA
according to the manufacturer’s instructions. Approximately
2.5 ng of cDNA was then used in the PCR on a StepOnePlus
Real-Time PCR System from Applied Biosystems. Triplicate
samples, validated endogenous controls, and inter-assay controls
were used throughout. The RT-qPCR results were analyzed by
SDS 2.2.2. For the AA group, let-7d* and miR-425* were chosen
for RT-qPCR validation (Table S2). For the CA group, let-7c and
miR-589 were chosen for RT-qPCR validation (Table S3, S4). So
far, there is no reliable endogenous control microRNA in studying
circulating microRNAs. We have surveyed the literature and
found that expression of miR-16 is relatively stable. Therefore, in
this study, we chose miR-16 as the endogenous control. RT-qPCR
data were the normalized expression values in which the
endogenous control miR-16 was used as the reference gene. For
each assay, the Ct (Cycle threshold) of miRNA of interest in the
TaqMan qPCR assay was subtracted from the average miR-16 Ct
Table 3. Differentially expressed microRNAs (P,0.05) with at least two-fold change obtained from comparisons in specimens from
AA and CA participants, respectively.
AA group (Case vs. Control) CA group (Case vs. Control)
MicroRNA Name Log2 FC P value AUC MicroRNA Name Log2 FC P value AUC
HS_242 2.522 0.043 0.73 hsa-miR-504 3.0135 0.014 0.76
hsa-miR-425* 2.313 0.003 0.79 HS_217 2.9009 0.012 0.78
hsa-miR-483-5p 1.992 0.034 0.61 hsa-miR-589 2.7814 0.013 0.62
hsa-miR-485-3p 1.977 0.016 0.61 solexa-578-1915 2.7638 0.009 0.84
hsa-miR-431 1.784 0.041 0.76 hsa-miR-595 2.6937 0.014 0.77
HS_183.1 1.7 0.037 0.69 hsa-miR-608 2.6538 0.015 0.76
hsa-miR-493 1.481 0.050 0.7 hsa-miR-219-5p 2.1339 0.04 0.77
hsa-miR-558 1.426 0.043 0.73 hsa-miR-1 1.8684 0.035 0.68
hsa-miR-331-5p 1.156 0.032 0.8 hsa-miR-431* 1.8289 0.01 0.77
hsa-miR-409-5p 21.007 0.012 0.64 hsa-miR-448 1.6971 0.025 0.6
hsa-miR-642 21.184 0.033 0.7 solexa-826-1288 1.6054 0.015 0.73
hsa-miR-505 21.572 0.017 0.58 hsa-miR-378 1.506 0.03 0.59
hsa-miR-377 21.591 0.041 0.75 solexa-9655-85 1.4611 0.023 0.78
HS_257 21.802 0.005 0.62 hsa-miR-551a 1.3358 0.041 0.74
hsa-miR-340* 21.85 0.041 0.63 hsa-miR-302b* 1.2173 0.028 0.86
hsa-miR-181a 22.054 0.034 0.69 hsa-miR-890 1.1176 0.024 0.78
hsa-miR-1304 22.624 0.023 0.76 hsa-miR-548l 1.0465 0.022 0.83
hsa-let-7d* 22.721 0.031 0.73 hsa-miR-873 21.013 0.04 0.52
hsa-miR-502-3p,hsa-miR-500* 21.276 0.041 0.6
hsa-miR-668 21.405 0.04 0.77
hsa-miR-610 21.458 0.016 0.66
hsa-let-7c 21.568 0.015 0.84
hsa-miR-155 21.684 0.02 0.74
hsa-miR-331-3p 21.831 0.03 0.5
hsa-miR-181a 21.954 0.043 0.76
hsa-miR-27b 21.994 0.021 0.67
hsa-miR-1304 22.397 0.036 0.62
hsa-miR-574-3p 22.463 0.03 0.8
hsa-miR-1275 22.629 0.014 0.77
hsa-miR-654-5p 22.758 0.021 0.82
hsa-miR-151-5p 23.522 0.002 0.76
The common microRNAs are underlined.
doi:10.1371/journal.pone.0013735.t003
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delta Ct value indicates a higher expression level of the miRNA of
interest.
Results
Demographic and clinical characterization of study
population
Twenty breast cancer cases (10 CAs and 10 AAs) and 20 healthy
controls (10 CAs and 10 AAs) were included in the analysis. The
cases and controls were well-matched on age (mean age: 56 vs 57,
P=0.562). All cases had histologically confirmed early stage (I and
II) invasive ductal carcinoma. Blood samples were drawn prior to
surgery. The tumor size ranged between 0.2 to 2.5 cm. ER, PR
and HER2/neu status data were available for 18 patients: 11 ER+,
7E R 2;1 0P R +,8P R 2; and 6 HER2/neu+, 12 HER2/neu2.
Four patients had triple negative breast cancer.
A large number of miRNAs are detected in plasma
The expression-detection P-value of Illumina Expression
BeadChips was used to quantify the number of miRNA detected
in the plasma of participants, designed to test the null hypothesis
that the expression intensity of a given miRNA is indistinguishable
from the background intensity. As shown in Table S1, among a
total of 1,145 miRNAs profiled by the chips, among CAs,there
were 886, 518 and 266 miRNAs detected (with detection
Pvalue,0.05) in the plasma of at least 1, 5, and 10 controls,
respectively. The corresponding number for case subjects in CA
group was 873, 503 and 278, respectively. Similar number of
miRNAs was detected in the plasma of AA participants (Table S1).
Overall, this demonstrates that plasma contains a large amount of
detectable miRNAs which provide a valuable repertoire that can
be used to discover circulating miRNA-based biomarkers for
breast cancer early detection.
Identification of differentially expressed miRNAs
At first, we made case-versus-control comparisons using all 40
participants (i.e.,2 0vs. 20). We identified 26 miRNAs with at
least two-fold differential expression at the significance level of
p,0.05 (Table 1), which reasonably separate the 20 cases from
the 20 controls (Figure 1A–B). Compared with the differentially
expressed miRNAs derived from case-versus-control comparisons
stratified by race, 10 of these 26 miRNAs can be derived using CA
group only, while 5 miRNAs can be derived using AA group only
(Figure 1C). There are 11, 19 and 9 miRNAs unique to the
comparison using AA group only, CA group only, and all 40
participants, respectively (Figure 1C). A total of 39 miRNAs are
specific to one of the three groups, compared with the 15 miRNAs
shared by two groups and 2 miRNAs shared by three groups,
suggesting a potential racial difference in circulating miRNAs.
Clearly, separate case-versus-control comparisons stratified by
race are necessary.
Figure 2. Characteristics of differentially expressed microRNAs (P,0.05 & FC .2) obtained from the case-versus-control
comparison. A–B) Hierarchical clustering and principal component clustering of miRNAs in samples from AA participants. D–E) Hierarchical
clustering and principal component clustering of miRNAs in samples from CA participants. C, F) The distribution of novel vs. known differentially
expressed miRNAs obtained from AA group and CA group, separately.
doi:10.1371/journal.pone.0013735.g002
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identified 31 miRNAs with at least two-fold differential expression
at the significance level of p,0.05, with 17 miRNAs up-regulated
in cases and 14 miRNAs down-regulated. Applying the same
criteria to the AA group, we identified 18 differentially expressed
miRNAs, with 9 miRNAs up-regulated in cases and 9 miRNAs
down-regulated. The number of identified differentially expressed
miRNAs (p,0.05) and the subgroup restricted by desired fold
change for each comparison are summarized in Table 2. A
detailed list of differentially expressed miRNAs with at least two-
fold expression change is shown in Table 3.
Characteristics of differentially expressed miRNAs
Remarkably, we found that there is little overlap between the
differentially expressed miRNAs identified from the CA groups
and those from the AA groups (Table 2–3). Only two of the 31
CA-derived miRNAs were also found in the 18 AA-derived
miRNAs, namely miR-181a and miR-1304. These results, while
preliminary, suggest that it might be necessary to develop race-
specific circulating miRNA based biomarkers in breast cancer
early detection.
The expression values of differentially expressed miRNAs
identified from each comparison were used to cluster the
participants into their corresponding case/control status. As
shown in Figure 2A–B, the 18 differentially expressed miRNAs
derived from the AA group reasonably separate the 10 cases from
the 10 controls. Similarly, the 31 differentially expressed miRNAs
derived from the CA group can reasonably separate the 10 cases
from the 10 controls (Figure 2D–E). The clustering results
demonstrate that the lists of differentially expressed miRNAs
derived from case-versus-control study might collectively serve as
potential circulating miRNA-based biomarkers in breast cancer
early detection.
The Illumina Human v2 MicroRNA Expression BeadChips
contains 1,145 miRNAs including 858 known miRNAs annotated
by miRBase (http://www.mirbase.org/) and 287 novel miRNAs
not found by miRBase (i.e., obtained from deep sequencing in
human tissues http://www.illumina.com/). In both AA and CA
groups, we found that novel miRNA constitute ,15% of identified
differentially expressed miRNAs (Figure 2C, 2F). For example, the
serum level of HS_242 and HS_217 are the first and second most
elevated in case vs. control in AA group and CA group,
respectively. As the rapidly developingd next-generation sequenc-
ing technique provides unprecedented power to discover and
characterize new miRNAs [34–35], it is expected that there will be
more currently-unfound circulating miRNA whose biomarker
potential remains to be explored.
Exploratory in silico pathway analysis
As the number of experimentally validated miRNA targets is
limited, we used the widely used TargetScan algorithm to obtain
the list of Entrez genes predicted to be targeted by the miRNAs
obtained from the AA study and CA study, respectively. We then
use NCBI DAVID server to identify the significantly enriched
canonical pathways (P,0.01) in these conserved targets. As
s h o w ni nF i g u r e3 ,a l t h o u g ht h e r ea r ef e wo v e r l a p sa tt h e
individual miRNA level, there is a much higher degree of
convergence at the pathway level regulated by identified
m i R N A s .S p e c i f i c a l l y ,2 7o f3 0e n r i c h e dp a t h w a y sr e g u l a t e db y
AA-derived miRNAs are also enriched in the predicted targets of
CA-derived miRNAs.
As shown in Table 4, pathways in cancer (KEGG: hsa05200) is one
of the most enriched pathways among the genes predicted to
regulated by AA-derived (P=3.78e
-09) and CA-derived (P=1.20
e-13)
miRNAs, respectively. This reassures the correctness of our
approach and indicates the potentially important functional role of
circulating miRNAs in tumor involvement. Pathways involved in
various signal transduction and cell-cell interactions such as ErbB
signaling pathways, Focal adhesion,a n dAdherens junction are also
significantly enriched in both AA and CA case-control comparisons.
Taken together, these exploratory analyses suggest that variation in
the plasma level of key circulating miRNAs might affect critical
pathways involved in breast cancer formation and progression, an
important mechanism warranting follow-up research. As miRNA
target prediction algorithm is known to contain both false positives
and false negatives, and our in silico pathway enrichment analysis is
based on mRNA genes predicted to be targeted by circulating
miRNAs, a full understanding of the potential functional role of
circulating miRNAs can only be established using functional
experiments.
Specific differentially expressed miRNAs
The expression levels of miRNA were confirmed with a
Taqman-based RT-qPCR. Let-7c and miR-589 were selected to
be validated in CA group and miR-425* and let-7d* were selected
to be validated in AA group. For the CA group, plasma levels of
let-7c were, in general, lower in cases than in controls (Fig 4A)
based on microarray profiling (FC=23.0, P=0.015). The
Figure 3. Venn diagrams showing the overlap at microRNA,
target gene and pathway levels, respectively. A) The differentially
expressed microRNAs (P,0.05 & FC .2). B) The target genes predicted
to be regulated by differentially expressed microRNAs. C) The enriched
pathways (P,0.01) in target genes predicted to be regulated by
differentially expressed microRNAs.
doi:10.1371/journal.pone.0013735.g003
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to build a ROC plot (Fig 4B), which reflects reasonable separation
between the two groups (AUC=0.84). To confirm the pattern of
let-7c is reproducible in independent participant cohorts, we
performed a validation study using 30 independent samples (15
cases vs. 15 controls). Taqman based miRNA RT-qPCR assays
were used to quantify the levels of plasma miRNAs in the
validation study. As shown in Figure 4C–D, a similar separation
pattern was observed in this independent cohort (FC =21.9,
P=0.01, AUC=0.78). MiR-589 was identified from the micro-
array study with up-regulation pattern for cases over controls in
CA group (Fold-Change=6.9, p=0.013). However, the separa-
tion is less obvious with an AUC value of 0.62 (Figure 5A–B),
which ranked it as a relatively weak candidate in our microarray-
Table 4. The list of enriched pathways (P,0.01) in the genes predicted to be targeted by differentially expressed microRNAs
(P,0.05) with at least two-fold change obtained from comparisons of case vs. control in AA and CA study subjects, respectively.
AA group (Case vs. Control) CA group (Case vs. Control)
Pathway Name P value Pathway Name P value
hsa04010:MAPK signaling pathway 3.03E-10 hsa05200:Pathways in cancer 6.86E-15
hsa05200:Pathways in cancer 3.78E-09 hsa04010:MAPK signaling pathway 1.20E-13
hsa04144:Endocytosis 1.05E-07 hsa04360:Axon guidance 1.97E-09
hsa04520:Adherens junction 9.67E-07 hsa04144:Endocytosis 4.43E-09
hsa04720:Long-term potentiation 6.64E-06 hsa04910:Insulin signaling pathway 5.85E-09
hsa04722:Neurotrophin signaling pathway 7.81E-06 hsa05210:Colorectal cancer 1.16E-08
hsa05211:Renal cell carcinoma 1.26E-05 hsa04722:Neurotrophin signaling pathway 2.56E-08
hsa04510:Focal adhesion 1.43E-05 hsa04810:Regulation of actin cytoskeleton 9.24E-08
hsa05220:Chronic myeloid leukemia 1.79E-05 hsa04510:Focal adhesion 1.78E-07
hsa04660:T cell receptor signaling pathway 2.29E-05 hsa05220:Chronic myeloid leukemia 4.16E-07
hsa04360:Axon guidance 2.30E-05 hsa05211:Renal cell carcinoma 5.67E-07
hsa04810:Regulation of actin cytoskeleton 3.10E-05 hsa05214:Glioma 1.11E-06
hsa04350:TGF-beta signaling pathway 5.33E-05 hsa04520:Adherens junction 3.04E-06
hsa05212:Pancreatic cancer 1.95E-04 hsa05212:Pancreatic cancer 4.32E-06
hsa05215:Prostate cancer 2.21E-04 hsa04310:Wnt signaling pathway 4.49E-06
hsa04012:ErbB signaling pathway 3.57E-04 hsa04720:Long-term potentiation 9.06E-06
hsa05218:Melanoma 4.13E-04 hsa05223:Non-small cell lung cancer 1.12E-05
hsa05210:Colorectal cancer 4.63E-04 hsa04350:TGF-beta signaling pathway 1.21E-05
hsa04310:Wnt signaling pathway 5.17E-04 hsa04930:Type II diabetes mellitus 2.20E-05
hsa05214:Glioma 0.001146 hsa05215:Prostate cancer 2.28E-05
hsa04666:Fc gamma R-mediated phagocytosis 0.001677 hsa04916:Melanogenesis 2.64E-05
hsa05414:Dilated cardiomyopathy 0.002158 hsa04660:T cell receptor signaling pathway 5.26E-05
hsa05219:Bladder cancer 0.002664 hsa04150:mTOR signaling pathway 5.53E-05
hsa04912:GnRH signaling pathway 0.002784 hsa05218:Melanoma 7.69E-05
hsa05410:Hypertrophic cardiomyopathy (HCM) 0.003003 hsa04012:ErbB signaling pathway 8.28E-05
hsa04916:Melanogenesis 0.00327 hsa05217:Basal cell carcinoma 4.94E-04
hsa05014:Amyotrophic lateral sclerosis (ALS) 0.005168 hsa05216:Thyroid cancer 6.56E-04
hsa04120:Ubiquitin mediated proteolysis 0.006743 hsa05219:Bladder cancer 0.001106
hsa04114:Oocyte meiosis 0.008262 hsa04020:Calcium signaling pathway 0.001243
hsa04330:Notch signaling pathway 0.008822 hsa04912:GnRH signaling pathway 0.001258
hsa05213:Endometrial cancer 0.001383
hsa04120:Ubiquitin mediated proteolysis 0.001384
hsa04114:Oocyte meiosis 0.001741
hsa04914:Progesterone-mediated oocyte maturation 0.001805
hsa04270:Vascular smooth muscle contraction 0.002534
hsa04666:Fc gamma R-mediated phagocytosis 0.002807
hsa05414:Dilated cardiomyopathy 0.003088
hsa05222:Small cell lung cancer 0.00502
hsa05221:Acute myeloid leukemia 0.006889
The common pathways are underlined.
doi:10.1371/journal.pone.0013735.t004
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Taqman based miRNA RT-qPCR assays were used to quantify its
expression level in the 30 independent samples (15 cases vs. 15
controls) described above. The RT-qPCR results show that this
microRNA is indeed characterized by an up-regulation (FC=3.3,
P=0.0009), and stronger separation is shown with an AUC value
of 0.85 (Figure 5C–D).
For the AA group, plasma levels of miR-425* (the minor form of
hsa-miR-425) were, in general, higher in cases compared with
controls (Fig 6A) based on microarray profiling (FC=5.0,
P=0.00328). The expression data of miR-425* in case and control
groups were used to build a ROC plot (Fig 6B), which reflects
reasonable separation between the two groups (AUC=0.79). To
check the accuracy of miR-425* expression pattern obtained from
microarray study, we used Taqman based miRNA RT-qPCR
assays as a golden-standard platform to quantify the levels of plasma
miRNAs in the same 20 samples. As shown in Figure 6C–D, a
similar separation pattern was observed (FC =3.3, P=0.01226,
AUC =0.83). Let-7d* was identified from the microarray study with
down-regulation pattern in cases over controls of AA group (FC =-
6.6, p=0.03063, AUC=0.73). Our RT-qPCR measurements in
the same 20 samples confirmed the microarray results, showing that
this microRNA is indeed down-regulated (FC=29.4, P=1.6–7),
and a close-to-perfect separation is shown with an AUC of 0.99
(Figure 7). While we found that microarray and RT-qPCR are
consistent in capturing the overall expression pattern of circulating
miRNA (i.e., up or down), the choice of different technology might
result in different sensitivity and specificity (e.g., AUC of 0.73 from
microarray vs. AUC of 0.99 from RT-qPCR for let-7d*).
Discussion
This is the first report of a comprehensive interrogation of
circulating miRNAs in breast cancer patients and healthy controls.
Our results demonstrate that circulating miRNAs in plasma can
potentially serve as novel minimally invasive biomarkers for early
detection of breast cancer. We found that 31 miRNAs were
significantly differentially expressed between CA cases and CA
controls and 18 miRNAs were significantly differentially expressed
between AA cases and AA controls. Using selected miRNAs from
those differentially expressed miRNAs, breast cancer cases and
healthy controls can be discriminated with reasonable specificity
and sensitivity. Intriguingly, there are only two differentially
expressed miRNAs overlapping between CA and AA study
subjects, suggesting potential racial differences in circulating
miRNA expression. In addition, in silico pathway-based explor-
atory analysis predicted that these differentially expressed
circulating miRNAs might affect critical pathways conducive to
breast cancer formation and progression, a potentially important
mechanism warranting further investigations.
Figure 4. Decreased plasma levels of let-7c for patients with breast cancer versus healthy controls in CA group. A–B) Data from
microarray profiling of 20 participants: The fold change of let-7c in case relative to control is 23.0 (P=0.015, AUC =0.84). C–D) Data from RT-qPCR
validation in an independent set of 30 participants: The fold change of let-7c in case relative to control is 21.9 (P=0.01, AUC =0.78).
doi:10.1371/journal.pone.0013735.g004
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up-regulated in CA study subjects and 9 out of 18 differentially
expressed miRNAs were up-regulated in AA study subjects.
Several of these up-regulated miRNAs have been reported to play
an important role in carcinogenesis. For example, miR-425*,a
minor form of miR-425, was significantly up-regulated in AA
breast cancer patients compared to AA healthy controls. Although
the role of miR-425* in human cancer is not clear, miR-425
was reported to be altered in cancer cell lines and tumor tissues
[36–37]. miR-425 resides at 3p21, next to miR-191 precursors
embedded in the 1st intron of DALRD3 gene. Significant
abundance and co-expression of miR-191 and miR-425 were
demonstrated in various cancer cell lines [36]. miR-425 is reported
to provide downregulation of ncRNA pathway via direct targeting
of DICER1 expression. miR-302b, which was significantly up-
regulated in CA breast cancer patients compared to CA healthy
controls, belongs to a panel of 12 miRNAs which are associated
with inflammatory breast cancer [38]. miR-302 family has been
demonstrated to directly regulate p21. In human mammary
epithelial cells, overexpression of miR-302b could modulate the
activity of p21 and consequently alter the oncogenic phenotypes.
In addition to up-regulated circulating miRNAs, we also observed
a similar number of down-regulated circulating miRNAs. For
example, we found the levels of circulating let-7c were significantly
higher in healthy controls than the cases. This is consistent with
the notion that let-7 family acts as tumor suppressor genes in breast
tumors. Recent studies have found that let family, especially let-7a,
7b and 7c, could inhibit cell proliferation and subsequently induce
apoptosis in MCF-7 breast cancer cell lines by directly regulating
ER-a [39].
The observation of decreased levels of circulating miRNAs in
breast cancer patients raises an interesting question concerning
the origin of circulating miRNAs and their potential functions in
breast tumorigenesis. Obviously, our observation cannot be
explained by the popular hypothesis that the origin of circulating
miRNAs is from tumor as a result of tumor cell death and lyses.
Alternatively, it is possible thatb o t hn o r m a la n dt u m o rc e l l sc a n
secrete certain miRNAs. Tumor cells may secrete miRNAs that
are transferable and functional in the recipient cells. However,
the biological significance of such actions is still unclear. Our
observations fit generally with this alternative hypothesis.
However, it is clear that further functional experiment studies
are needed to solve the question of the origin of circulating
miRNAs.
In a previous breast cancer study, Heneghan et al [26] surveyed
a small panel of 7 candidate miRNAs in whole blood RNAs from
148 breast cancer patients and 44 age-matched and disease free
controls. They found the expression of miR-195 was significantly
higher in breast cancer patients than healthy controls (P,0.001).
In addition, they found the expression of let-7a, which is well-
Figure 5. Increased plasma levels of miR-589 for patients with breast cancer versus healthy controls in CA group. A–B) Data from
microarray profiling of 20 participants: The fold change of miR-589 in case relative to control is 6.9 (P=0.0131, AUC =0.62). C–D) Data from RT-qPCR
validation in an independent set of 30 participants: The fold change of miR-589 in case relative to control is 3.3 (P=0.0009, AUC =0.85).
doi:10.1371/journal.pone.0013735.g005
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in breast cancer, was increased over 5-fold in breast cancer
patients compared to healthy controls (P,0.001). In our study, we
did not observe differential expression for miR-195 (P=0.169) or
let-7a (P=0.106) between cases and controls. The discrepancy
between two studies might be due to different study materials. The
Heneghan study used whole blood for detection of miRNAs, while
we used plasma for our analyses. Whole blood contains different
types of cells, so miRNAs detected might be circulating miRNAs
as well as cellular miRNAs from additional cells types. The
discrepancy might also reflect the heterogeneity of breast cancer.
Different molecular pathways are involved in different subtypes of
breast cancer, with different molecular characterizations between
luminal A, luminal B, and basal like subtypes. In the Heneghan
study, 59% of breast cancers were stage I and II, 71% were
invasive ductal cancer, and 82% were ER positive. Meanwhile, in
our study, all patients had stage I and II invasive ductal cancer,
and only 55% of patients were ER positive. These differences in
clinical characteristics, together with the relatively small sample
size used in this study, might contribute to the difference between
their study and our study. In our ongoing validation study, we
have significantly increased sample size and included different
subtypes of breast cancer. Hopefully, this will give us an
opportunity to validate our findings in this study as well as test
the predictive value of miR-195 and let-7a.
Another interesting observation from our study is the potential
racial difference in terms of differentially expressed miRNAs
between CA and AA study specimens. In the United States, breast
cancer mortality is higher among AA women compared to women
of European ancestry (EA). Breast cancer in AA women is
characterized by earlier age at onset, later stage at diagnosis,
higher nuclear grade, higher mitotic index and lower prevalence
of estrogen receptor (ER) and/or progesterone receptor (PR)
expression compared with EA women [40]. However, whether
the genetic alterations leading to breast carcinogenesis are
different between AA and CA breast cancer patients is not clear.
More intriguingly, we found that the in silico predicted biological
pathways were similar between CA and AAs although their
miRNA expression profiles were different. This is consistent with
the clinical observations that the course of breast cancer may be
characterized by certain common pathways and the balance
between tumor and host traits influences the pace of the common
pathways. However, it should be emphasized that our observa-
tions are exploratory in nature and need to be assessed in further
studies with larger sample size. More importantly, functional
experiments are required to verify and establish the causal
Figure 6. Increased plasma levels of miR-425* for patients with breast cancer versus healthy controls in AA group. A–B) Data from
microarray profiling of 20 participants: The fold change of miR-425* in case relative to control is 5.0 (P=0.00328, AUC =0.79). C–D) Data from RT-
qPCR validation in the same 20 participants: The fold change of miR-425* in case relative to control is 3.3 (P=0.01226, AUC =0.83).
doi:10.1371/journal.pone.0013735.g006
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predicted pathways.
One limitation of this study is the relatively small samplesize which
does not provide us enough power to assess relationships between
levels of circulating miRNAs and clinical characteristics. To achieve
an 80% power to detect a gene expression difference of 2-fold and
above, we will need 18 pairs of samples, assuming a set of 1,145
human miRNA genes on the microarray, a standard deviation of 0.7,
1 expected false positive, and an adjusted P-value of 0.001 (http://
bioinformatics.mdanderson.org/MicroarraySampleSize).
Also, as we observed in the study, there might be unknown
nc-RNAs existing in the circulation, which cannot be studied
using microarray analysis relying on pre-designed probes. Some
of these nc-RNAs might have important predictive values and
significant functional roles in breast carcinogenesis. The rapidly
developing massive parallel sequencing technology is not
dependent on any prior probe information, instead providing
information about all known microRNAs in the sample and
allowing for discovery of novel microRNAs [35]. In our data, we
found that novel miRNAs constitute ,15% of identified
differentially expressed miRNAs. Nevertheless, this is the first
genome-wide study to comprehensively survey the circulating
miRNAs in breast cancer patients and healthy controls. The
results presented here show significantly altered circulating
levels of certain miRNAs in breast cancer patients compared
with healthy controls. Due to the genetic and clinical
heterogeneity of breast cancer, some of the separation is not
perfect. Therefore, the data should be interpreted with caution.
Future large studies and advanced technologies are warranted to
confirm our findings and further explore the existing potential of
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Figure 7. Decreased plasma levels of let-7d* for patients with breast cancer versus healthy controls in AA group. A–B) Data from
microarray profiling of 20 participants: The fold change of let-7d* in case relative to control is 26.6 (p=0.03063, AUC=0.73). C-D) Data from RT-qPCR
validation in the same 20 participants: The fold change of let-7d* in case relative to control is 29.4 (P=1.6e-7, AUC =0.99).
doi:10.1371/journal.pone.0013735.g007
Plasma miRNAs Breast Cancer
PLoS ONE | www.plosone.org 11 October 2010 | Volume 5 | Issue 10 | e13735Acknowledgments
We thank Dr. Warren Davis and Ms. Mary Nesline, the Co-Directors of
DataBank and Biorepository (DBBR) in Roswell Park Cancer Institute, for
proving high-quality biospecimens and related data for this study. The
Roswell Park Cancer Institute DBBR is a CCSG Shared Resource (NIH
P30 CA016056-27).
Author Contributions
Conceived and designed the experiments: HZ CBA SL. Performed the
experiments: JS LM. Analyzed the data: DW SL. Contributed reagents/
materials/analysis tools: SL. Wrote the paper: HZ JS SL.
References
1. Taplin S, Abraham L, Barlow WE, Fenton JJ, Berns EA, et al. (2008)
Mammography facility characteristics associated with interpretive accuracy of
screening mammography. J Natl Cancer Inst 100: 876–887.
2. Thompson A, Brennan K, Cox A, Gee J, Harcourt D, et al. (2008) Evaluation of
the current knowledge limitations in breast cancer research: a gap analysis.
Breast Cancer Res 10: R26.
3. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, et al.
(2005) Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after
adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:
1659–1672.
4. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, et al. (2007) American
Society of Clinical Oncology. American Society of Clinical Oncology 2007
update of recommendations for the use of tumor markers in breast cancer. J Clin
Oncol 25: 5287–5312.
5. O’Hanlon DM, Kerin MJ, Kent P, Maher D, Grimes H, et al. (1995) An
evaluation of preoperative CA 15–3 measurement in primary breast carcinoma.
Br J Cancer 71: 1288–1291.
6. Uehara M, Kinoshita T, Hojo T, Akashi-Tanaka S, Iwamoto E, et al. (2007)
Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohy-
drate antigen 15–3 (CA 15–3) in breast cancer. Int J Clin Oncol 13: 447–451.
7. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, et al. (2005) MicroRNA
expression profiles classify human cancers. Nature 435: 834–838.
8. Esquela-Kerscher A, Slack FJ (2006) Oncomirs - microRNAs with a role in
cancer. Nat rev Cancer 6: 259–269.
9. Johnson R, Zuccato C, Belyaev ND, Guest DJ, Cattaneo E, et al. (2008) A
microRNA-based gene dysregulation pathway in Huntington’s disease. Neuro-
biol dis 29: 438–445.
10. Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, et al. (2008)
MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor
Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer.
Oncogene 27: 2128–2136.
11. Huang Q, Gumireddy K, Schrier M, le Sage C, Nagel R, et al. (2008) The
microRNAs miR-373 and miR-520c promote tumor invasion and metastasis.
Nature cell biol 10: 202–210.
12. Ma L, Teruya-Feldstein J, Weinberg RA (2007) Tumor invasion and metastasis
initiated by microRNA-10b in breast cancer. Nature 449: 682–688.
13. Zhu S, Si ML, Wu H, Mo YY (2007) MicroRNA-21 targets the tumor
suppressor gene tropomyosin 1 (TPM1). J Biol Chem 282: 14328–14336.
14. Zhu S, Wu H, Wu F, Nie D, Sheng S, et al. (2008) MicroRNA-21 targets tumor
suppressor genes in invasion and metastasis. Cell Res 18: 350–359.
15. Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, et al. (2008)
Endogenous human microRNAs that suppress breast cancer metastasis. Nature
451: 147–152.
16. Valastyan S, Reinhardt F, Benaich N, Calogrias D, Sza ´sz AM, et al. (2009) A
pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell
137: 1032–1046.
17. Hurst DR, Edmonds MD, Welch DR (2009) Metastamir: the field of metastasis-
regulatory microRNA is spreading. Cancer Res 69: 7495–7498.
18. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, et al. (2005) MicroRNA
gene expression deregulation in human breast cancer. Cancer Res 65:
7065–7070.
19. Mattie MD, Benz CC, Bowers J, Sensinger K, Wong L, et al. (2006) Optimized
high-throughput microRNA expression profiling provides novel biomarker
assessment of clinical prostate and breast cancer biopsies. Mol Cancer 5: 24.
20. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, et al. (2008)
Detection of elevated levels of tumor-associated microRNAs in serum of patients
with diffuse large B-cell lymphoma. Br J Haematol 141: 672–675.
21. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, et al. (2008)
Circulating microRNAs as stable blood-based markers for cancer detection. Proc
Natl Acad Sci USA 105: 10513–10518.
22. Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, et al. (2008) Serum
MicroRNAs are promising novel biomarkers. PLoS One 3: e3148.
23. Chen X, Ba Y, Ma L, Cai X, Yin Y, et al. (2008) Characterization of
microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and
other diseases. Cell Res 18: 997–1006.
24. Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, et al. (2009) The
detection of differentially expressed microRNAs from the serum of ovarian
cancer patients using a novel real-time PCR platform. Gynecol Oncol 112:
55–59.
25. Wang K, Zhang S, Marzolf B, Troisch P, Brightman A, et al. (2009) Circulating
microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad
Sci USA 106: 4402–4407.
26. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, et al. (2010)
Circulating microRNAs as novel minimally invasive biomarkers for breast
cancer. Ann Surg 251: 499–505.
27. Huang Z, Huang D, Ni S, Peng Z, Sheng W, et al. (2010) Plasma microRNAs
are promising novel biomarkers for early detection of colorectal cancer. Int J of
Cancer 127: 118–126.
28. Lodes MJ, Caraballo M, Suciu D, Munro S, Kumar A, et al. (2009) Detection of
Cancer with Serum miRNAs on an Oligonucleotide Microarray. PLoS ONE 4:
e6229.
29. Ambrosone CB, Nesline MK, Davis W (2006) Establishing a cancer center data
bank and biorepository for multidisciplinary research. Cancer Epidemiol
Biomarkers Prev 15: 1575–1577.
30. Smyth GK (2004) Linear models and empirical Bayes methods for assessing
differential expression in microarray experiments. Stat Appl Genet Mol Biol 3:
R3.
31. Eisen MB, Spellman PT, Brown PO, Botstein D (1998) Cluster analysis and
display of genome-wide expression patterns. Proc Natl Acad Sci USA 95:
14863–14868.
32. Sing T, Sander O, Beerenwinkel N, Lengauer T (2005) ROCR: visualizing
classifier performance in R. Bioinformatics 21: 3940–3941.
33. Huang W, Sherman BT, Tan Q, Kir J, Liu D, et al. (2007) DAVID
Bioinformatics Resources: expanded annotation database and novel algorithms
to better extract biology from large gene lists. Nucleic Acids Res 35: W169–75.
34. Morozova O, Hirst M, Marra MA (2009) Applications of new sequencing
technologies for transcriptome analysis. Annu Rev Genomics Hum Genet 10:
135–151.
35. Friedlaender MR, Chen W, Adamidi C, Maaskola J, Einspanier R, et al. (2008)
Discovering microRNAs from deep sequencing data using miRDeep. Nature
Biotechnol 26: 407–415.
36. Grinchuk OV, Jenjaroenpun P, Orlov YL, Zhou J, Kuznetsov VA (2010)
Integrative analysis of the human cis-antisense gene pairs, miRNAs and their
transcription regulation patterns. Nucleic Acids Res 38: 534–547.
37. Selcuklu SD, Yakicier MC, Erson AE (2009) An investigation of microRNAs
mapping to breast cancer related genomic gain and loss regions. Cancer Genet
Cytogenet 189: 15–23.
38. Van der Auwera I, Van Laere S, Limame R, Trinh X, Van Marck E, et al.
(2009) A microRNA Expression Profile Consisting of 12 microRNAs Is
Associated with Inflammatory Breast Cancer. Cancer Res 69: 6119.
39. Zhao Y, Deng C, Wang J, Xiao J, Gatalica Z, Recker RR, Xiao GG. Let-7
family miRNAs regulate estrogen receptor alpha signaling in estrogen receptor
positive breast cancer. Breast Cancer Res Treat, 2010 Jun 10 [Epub ahead of
print].
40. Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, et al.
Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008
May;109(1): 123–39.
Plasma miRNAs Breast Cancer
PLoS ONE | www.plosone.org 12 October 2010 | Volume 5 | Issue 10 | e13735